Lupin alters generic Truvada, Viread plans
This article was originally published in Scrip
Executive Summary
Lupin will not pursue plans to market generic versions of Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate) before the expiration of the four patents associated with tenofovir in January 2018 (including pediatric exclusivity) as part of what some analysts see as a calibrated effort by the Indian firm to defocus on products with limited earnings potential.